Overview
Fabric Genomics provides AI-powered genomic analysis and reporting for hospitals, research labs, and diagnostic centers through a SaaS platform called Fabric Enterprise. It analyzes Next-Generation Sequencing data from whole genomes, exomes, and gene panels, turning sequencing results into interpreted variants and clinical reports using its Fabric GEM AI. The platform also automatically reanalyzes undiagnosed cases over time to update findings, delivering faster and more accurate results. Its differentiators are AI-driven interpretation, support for multiple NGS data types, and ongoing reanalysis delivered via a scalable subscription model aimed at speeding diagnoses and lowering healthcare costs.
Work here?Claim your company
Simplify's take
What believers are saying
- May 2026 filings confirmed Fabric generated $2.5 million in Q1 2026 revenue.
- SEC filings show GeneDx kept Fabric through June 30, 2026, despite impairment charges.
- October 2025 FDA Breakthrough Device designation widens GeneDx’s clinical commercialization runway.
What critics are saying
- GeneDx wrote down $31.2 million tied to Fabric on May 4, 2026.
- A June 2026 class action alleges Fabric misled investors and crushed WGS 49%.
- Fabric remaining international-only invites GeneDx to unwind the unit and erase its standalone business.
What makes Fabric Genomics unique
- Fabric’s AI interpretation platform speeds rare-disease and oncology reporting across WGS, exomes, panels.
- GeneDx closed Fabric acquisition May 7, 2025, embedding software into a clinical testing stack.
- Intermountain, Broad Clinical Labs, and PlumCare validate Fabric in pediatric and newborn programs.
Help us improve and share your feedback! Did you find this helpful?